The term Xanthelasma (Xanthelasma palpebrarum) is derived from the Greek ξανθός, xanthos (yellow) and έλασμα, élasma (foil), and identify a xanthomatous inflammation of the eyelid. (3) Xanthelasma consist in single or multiple soft yellow plaques/papules caused by localized accumulation of lipid deposits on the eyelids, mainly in medial canthal region of the eyelids. It can be bilateral. (4)
Xanthelasmata can be soft, semisolid, or calcareous. Frequently, they are symmetrical. The upper lids are more frequently involved than the lower lids. Often, the four lids are involved. Xanthelasmata have a tendency to progress, coalesce, and become permanent. (5)
Fifty patients were selected, with an average age of fifty-four, all suffering from Xanthelasma palpebrarum. A clinical evaluation of each patient was performed and all those who did not present contraindications to the surgical therapy were enrolled in the study. Il dispositivo utilizzato era Plasmage ®, di Brera Medical Technologies S.r.l., Italia.
Alla fine del trattamento, a tutti i pazienti è stato assegnato un test di valutazione della soddisfazione.
Based on our experience, we can state that plasma ablative surgery (Plasmage, by Brera Medical Technologies S.r.l., Italy), is safe, easy to perform, does not produce scars, and is good for patients.
This new non-invasive surgical thecnique is also indicated for therapy of dermatochalsis (blepharoplasty), and of most benign eyelid lesions, as squamous papilloma (also called fibroepithelial polyp or skin tag). Finally, Plasmage can be used for treatment of skin dyschromias, and smooth out wrinkles.
Surely, more studies will be needed to confirm our results, but the clinical experience to date is very positive.
Dr Jacques André David - Dr Dorina Cheles
If you wish to receive the internal study, contact us using the form on this site and request the internal study xanthelasma treated with Plasmage
2 Kashkouli M.B., Abdolalizadeh P., Abolfathzadeh N., Sianati H., Sharepour M., Hadi Y.: “Periorbital Facial Rejuvenation; Applied Anatomy and Pre-operative Assessment”. J Curr Ophthalmol. 2017; 29(3): 154-168.
3 Frew J.W., Murrell D.F., Haber R.M.: “Fifty Shades of Yellow: a Review of the Xanthodermatoses”. Int J Dermatol. 2015; 54(10):1109–1123.
4 Laftah Z., Al-Niaimi F.: “Xanthelasma: An Update on Treatment Modalities”. J Cutan Aesthet Surg. 2018;11(1): 1-6.
5 Nair P.A., Singhal R.: “Xanthelasma Palpebrarum – a Brief Review”. Clin Cosmet Investig Dermatol. 2018; 11: 1-5.
6 Jee MS, Chang SE, Choi JH, et al.: “Clinicopathologic Study of 37 Cases of Xanthelasma Palpebrarum; Clinical Significance of Xanthelasma Palpebrarum in Hyperlipidemiae and Cardiovascular Diseases”. Korean J Dermatol. 2003; 41:333–337.
7 Bergman R.: “The Pathogenesis and Clinical Significance of Xanthelasma Palpebrarum”. J Am Acad Dermatol.1994;30:236-42.
8 Tursen U, Eskandari G, Kaya TI, Tamer L, Ikizoglu G, Atik U.: “Apolipoprotein E Polymorphism and Lipoprotein Compositions in Normolipidaemic Xanthelasma Patients”. J Eur Acad Dermatol Venereol. 2006; 20:260-3.
9 Kim J., Kim Y.J., Lim H., Lee S.I.: “Bilateral Circular Xanthelasma Palpebrarum”. Arch Plast Surg. 2012; 39(4): 435-437.
10 Roder D.J., Hobbs H.H.: “Disorders of Lipoprotein Metabolism”. In: Longo D.L., Fauci A.S., Kasper D.L., Hauser S.L., Jameson J.L., Loscalzo J. (Eds.): “Harrison’s Principles of Internal Medicine” (18th Ed.). McGraw-Hill Medical, New York, 2012.
11 Christoffersen M., Frikke-Schmidt R., Schnohr P., Jensen G.B., Nordestgaard B.G., Tybjærg-Hansen A.: “Xanthelasmata, Arcus Corneae, and Ischaemic Vascular Disease and Death in General Population: Prospective Cohort Study”.BMJ. 2011; 343: d5497.
12 Lee H.Y., Jin U.S., Minn K.W., Park Y.O.: “Outcomes of Surgical Management of Xanthelasma Palpebrarum”. Arch Plast Surg. 2013; 40:380–6.
13 Pathania V., Chatterjee M.: “Ultrapulse Carbon Dioxide Laser Ablation of Xanthelasma Palpebrarum: A Case Series”. J Cutan Aesthet Surg. 2015; 8:46–9.
14 Esmat S.M., Elramly A.Z., Abdel Halim D.M., Gawdat H.I., Taha H.I.: “Fractional CO2 Laser is an Effective Therapeutic Modality for Xanthelasma Palpebrarum: A Randomized Clinical Trial”. Dermatol Surg. 2014; 40:1349–55.
15 Labandeira J., Vázquez-Osorio I., Figueroa-Silva O., Pereiro M. Jr., Toribio J.: “Tolerability and Effectiveness of Liquid Nitrogen Spray Cryotherapy with Very Short Freeze Times in the Treatment of Xanthelasma Palpebrarum”. Dermatol Ther. 2015; 28:346–50.
16 Wang H., Shi Y., Guan H., Liu C., Zhang W., Zhang Y., et al.: “Treatment of Xanthelasma Palpebrarum with Intralesional Pingyangmycin”. Dermatol Surg. 2016; 42:368–76.
17 Goldston R.J., Rutherford P.H.: “Introduction to Plasma Physics” (1th Ed.). CRC Press, USA, 1995.
18 Goldschmidt H. (Ed.): “Physical Modalities in Dermatologic Therapy”. Springer, New York, 1978.